| CAT. No. | MRL-A40001 |
| CAS. No. | 1420477-60-6 |
| Mol. Formula | C26H23N7O2 |
| Mol. Weight | 465.52 |
| Synonyms | NA |
| Chemical Name | (S)-4-(8-Amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
| HSN Code | 38229010 |
| Country of Origin | India |
| Stock Status | Custom Synthesis |
Acalabrutinib is a small molecule inhibitor of Brutons tyrosine kinase (BTK), primarily used for the treatment of certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Chemically, it belongs to the class of drugs known as irreversible BTK inhibitors, which work by binding covalently to the BTK enzyme, thereby inhibiting its activity. By blocking BTK signaling pathways, acalabrutinib interferes with the survival and proliferation of cancerous B cells, leading to tumor regression. Its specificity for BTK and favorable safety profile make it a promising targeted therapy for these malignancies, especially for patients who have relapsed or are intolerant to other treatments. Buy high quality Acalabrutinib from Molsyns Research. Molsyns Research is one of the leading manufacturer and exporter of Acalabrutinib.